Article Type
Review
Published
Tag: immunotherapy
Article Type
Review
Published
This article reviews the cutaneous side effects of main molecularly targeted cancer therapies for solid tumors.
Article Type
Review
Published
Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).
Article Type
Editorial
Published
This editorial describes the results of the most recent clinical trials on the use of immunotherapies in renal cell carcinoma and research for reliable biomarkers of tumour response in this setting, as well as the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies.
Article Type
Review
Published
This article examines the major approaches to immunotherapy in breast cancers, both successes and failures, as well as new therapies on the horizon.
